China's chemical and pharmaceutical industry companies announced that the top three rankings have changed

[ Chemical Machinery Equipment Network Star Enterprise ] On October 13, the "2020 China Chemical and Pharmaceutical Industry Outstanding Enterprises and Excellent Product Brands" list was announced.
This list is one of the most influential brands in the domestic pharmaceutical industry.

 

In terms of the comprehensive strength list of industrial enterprises in China's chemical and pharmaceutical industry in 2020, Yangzijiang Pharmaceutical, Shanghai Pharmaceuticals, and Hengrui Pharmaceuticals ranked the top three in this list, followed by Fosun Pharmaceuticals and Chia Tai Tianqing.
*Enterprises also include Kelun Pharmaceutical, Qilu Pharmaceutical, AstraZeneca, Lunan Pharmaceutical, and Hausen Pharmaceutical.

 

Among them, Yangtze River Pharmaceutical has ranked first in the comprehensive strength list of industrial enterprises in the chemical and pharmaceutical industry for 6 consecutive years.
In 2019, Yangzijiang Pharmaceutical Group achieved sales and profits and taxes increased by 11.
94% and 16.
2% year-on-year respectively, and its comprehensive strength reached a new height.

 

It is reported that the company has always adhered to the main business of medicine, adhering to the core values ​​of "high quality, benefiting the people, innovation, and perfection", implementing the "three-wheel drive" development strategy of innovation, quality and branding, deploying a large health industry from a high starting point, and deepening the supply side Structural reforms have made unremitting efforts to revitalize national medicine and benefit human health.
Among them, a large number of well-known and high-quality products such as Dezocine, Lanqin Oral Liquid and Suhuang Cough Capsules maintain a relatively high market share.
In addition, the company pursues a quality culture of "pharmaceuticals for parents and relatives" and a brand culture of "Yangtze River water nurtures China and Yangtze River medicine benefits China" to achieve the coordinated development of brands and markets, and simultaneously improve quality and efficiency.

 

　　Shanghai Pharmaceuticals still ranks second on the list.
The company adheres to the direction of innovative development and regards the provision of safe and effective treatments for major diseases and chronic diseases as its development focus.
Relying on its fruitful research and development results, Shanghai Pharmaceuticals' research and development strength has also been highly recognized in the industry; and compared with the previous year's list, Hengrui Pharmaceuticals has advanced one place over Fosun Pharmaceuticals, which shows that its research and development strength and innovation results continue to appear.
.

 

　　It is worth mentioning that CP Tianqing once again climbed its ranking compared with the previous year.
The company is an innovative pharmaceutical group enterprise integrating scientific research, production and sales.
For decades, the company has always regarded R&D and innovation as an important strategy for corporate development, and has gradually formed a complete R&D and innovation system and competitive advantage.
In recent years, CP Tianqing has been committed to building six product clusters for liver disease, tumor, respiratory, infection, endocrine and cardiovascular and cerebrovascular products, with more than 170 products under development, including more than 30 new drugs of the first category and more than 20 biological drugs.

 

　　This time, CP Tianqing Pharmaceutical Group won the two awards of "2020 Comprehensive Strength of Industrial Enterprises in China's Chemical and Pharmaceutical Industry" and "2020 China's Chemical and Pharmaceutical Industry Innovative Outstanding Enterprise Brand", and won 19 awards, including anti-tumor first-class new drug safety Rotinib won the "2020 China Chemical Pharmaceutical Industry Innovative Drug Special Award".

 

　　Anlotinibron is an innovative anti-tumor drug independently developed by Chia Tai Tianqing for more than ten years and costing more than one billion yuan.
As a new type of small molecule multi-target tyrosine kinase inhibitor, Anlotinib Hydrochloride Capsule provides an effective new treatment for the third-line treatment of patients with advanced non-small cell lung cancer in China, becoming the first approved advanced non-small cell lung cancer in the country.
Third-line treatment for cell lung cancer.
After the launch of Anlotinib Hydrochloride Capsules, it quickly entered the team that supported the national Class 1 new drug and the national “Major New Drug Creation” major scientific and technological project, and became a domestically developed original innovative drug that was successfully negotiated on the national medical insurance for anticancer drugs in 2018.
CP Tianqing has won many awards this time, which also shows the manifestation of its innovative development achievements.

 

　　Original title: China's chemical and pharmaceutical industry companies announced that the top three rankings have changed